Core Viewpoint - The company, Lifesun Pharmaceutical, has received drug registration certificates from the National Medical Products Administration for its potassium chloride sustained-release tablets in 0.5g and 0.6g specifications, indicating successful approval for market entry [1]. Group 1 - The potassium chloride sustained-release tablets are indicated for the treatment and prevention of hypokalemia with or without metabolic alkalosis [1]. - These tablets are particularly useful for patients who do not respond well to dietary management with potassium-rich foods or reduced diuretic dosage [1].

Core Viewpoint - The company, Lifesun Pharmaceutical, has received drug registration certificates for its potassium chloride sustained-release tablets in two specifications, indicating successful approval for market entry [1] Group 1: Company Developments - Lifesun Pharmaceutical announced the receipt of drug registration certificates from the National Medical Products Administration for potassium chloride sustained-release tablets in 0.5g and 0.6g specifications [1] - The potassium chloride sustained-release tablets are indicated for the treatment and prevention of hypokalemia associated or not associated with metabolic alkalosis, particularly when dietary management or reduced diuretic dosage is ineffective [1]

证券代码：002393 证券简称：力生制药 公告编号：2025-059 天津力生制药股份有限公司 关于药品氯化钾缓释片通过上市许可申请的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 四、对本公司的影响及风险提示 公司该药品通过上市许可申请，将进一步丰富公司治疗消化系统疾病药物产品线， 提高公司市场竞争力。根据国家相关政策，公司产品氯化钾缓释片按化学药品3类批准 生产，可视同通过一致性评价，这将有利于扩大公司产品的市场销售，对公司的未来经 营业绩产生积极影响。由于医药产品的行业特点，各类产品/药品的具体销售情况可能 受到市场环境变化等因素影响，具有较大不确定性，敬请广大投资者注意投资风险。 特此公告。 天津力生制药股份有限公司 二、该药品的基本情况 | 药品名称 | | 氯化钾缓释片 | | | --- | --- | --- | --- | | 剂 | 型 | 片 剂 | | | 规 | 格 | 0.5g | 0.6g | | 注册分类 | | 化学药品 | | | 药品生产企业 | | 天津力生制药股份有限公司 | | | 原药品批准文号 | | 无 ...

Core Viewpoint - The company has received drug registration certificates for two specifications of potassium chloride sustained-release tablets, indicating successful approval for market entry [1] Group 1 - The company announced the receipt of the drug registration certificate for potassium chloride sustained-release tablets in 0.5g specification [1] - The company also received the drug registration certificate for potassium chloride sustained-release tablets in 0.6g specification [1] - Both products have successfully passed the drug market licensing application [1]

Key Points - The article discusses significant events in the private equity fund market from August 18 to August 24, highlighting various fund establishments and their focus areas [5]. Government-Backed Funds - Changjiang Gengzhi Fund has completed registration with a total scale of 3 billion yuan, focusing on new materials and high-end equipment [7]. - Jiangsu Xuzhou New Industry Special Mother Fund has been established with a total scale of 3 billion yuan, targeting emerging industries like new energy and integrated circuits [8]. - Lishui City has set up a 2 billion yuan venture capital fund, emphasizing early-stage investments in technology-driven startups [9]. - Fujian Province has initiated a 1 billion yuan publishing industry mother fund, focusing on cultural industry integration [9]. - A 3 billion yuan semiconductor industry fund has been established in Ezhou, targeting the semiconductor industry chain [9]. Market-Oriented Funds - Tencent-related companies have launched a fund in Shenzhen with a scale of approximately 16.08 billion yuan, focusing on investment activities and enterprise management [16]. - QFLP projects have been established in Kunshan and Tianjin, with a focus on technology and medical innovation sectors [16][18]. - KKR has launched its first onshore RMB fund in Shanghai, indicating its commitment to the Chinese market [18][19]. Industry-Specific Funds - Huadong Medicine has participated in establishing a 2 billion yuan specialized pharmaceutical industry fund, focusing on innovative drugs and health sectors [21]. - Tianjin Lisheng Pharmaceutical is setting up a 1 billion yuan industry fund, targeting the health and biotechnology sectors [22]. - Visual China has invested in a 500 million yuan industry merger fund, focusing on AI and high-end equipment manufacturing [23]. Emerging Trends - The establishment of various funds indicates a growing trend towards specialized investments in sectors such as artificial intelligence, new materials, and healthcare [10][11][12][14][15]. - The collaboration between government and private sectors is evident in the formation of these funds, aiming to enhance local industry development and innovation [6][8][9].

Group 1: Financial Support for Forestry and Carbon Market Development - The People's Bank of China, financial regulatory authorities, and the National Forestry and Grassland Administration jointly issued a notice to enhance financial support for high-quality development in forestry, focusing on expanding mortgage loan products and services related to forest rights [2] - The notice encourages the establishment of forest rights storage institutions and the involvement of social capital in guarantee services, as well as the optimization of forest rights value assessment mechanisms [2] - The State Council's opinion on promoting green and low-carbon transformation emphasizes the importance of the carbon market as a policy tool for addressing climate change and accelerating green transformation [2] Group 2: Real Estate Policy Adjustments in Shanghai - Shanghai's housing and urban construction authorities issued a notice to optimize and adjust real estate policies, including reducing housing purchase restrictions and improving housing provident fund and personal housing loan policies, effective from August 26, 2025 [4] Group 3: Innovation in Pharmaceutical Industry - The innovation drug sector is experiencing increased activity, with notable stock price increases for companies such as Hitec Biotech, which rose by 20%, and several others reaching their daily limit [6] - The National Medical Products Administration reported that China's pharmaceutical industry ranks second globally, with approximately 30% of innovative drugs under development [6] Group 4: Developments in the Photovoltaic Industry - The photovoltaic sector is seeing a surge in activity following the China Photovoltaic Industry Association's initiative to strengthen industry self-discipline and promote fair competition [7] - Leading companies in the photovoltaic industry, such as Robotech and Daqo New Energy, have experienced significant stock price increases as a result of this initiative [7] Group 5: Company Performance and Strategic Moves - Zhangyuan Tungsten's revenue for the first half of the year reached 2.399 billion yuan, a year-on-year increase of 32.27%, while net profit grew by 2.54% [8] - Xizang Zhuofeng reported a revenue of 1.123 billion yuan, up 53.53%, with net profit increasing by 135.08% [8] - Aoyijin and Sleek signed a strategic cooperation agreement for production equipment and services, with an expected total investment of 500 million yuan over five years [9] - Huayi Technology is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international presence and competitiveness [11]

证券日报网讯 8月25日晚间，力生制药发布公告称，公司将参加由天津证监局指导、天津上市公司协会 及深圳市全景网络有限公司联合举办的"2025年天津辖区上市公司投资者网上集体接待日活动"。 （编辑 姚尧） ...

证券代码：002393 证券简称：力生制药 公告编号：2025-058 天津力生制药股份有限公司 关于参加2025年天津辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，天津力生制药股份有限公司（以下简称"公司"）将 参加由天津证监局指导、天津上市公司协会及深圳市全景网络有限公司联合举办的"2025年 天津辖区上市公司投资者网上集体接待日活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站（http://rs.p5w.net）； 或关注微信公众号（名称：全景财经）；或下载全景路演APP，参与本次互动交流。活动时 间为2025年9月11日（周四）15:00-17:00。出席本次活动的有公司独立董事方建新先生、财 务总监王家颖先生和董事会秘书马霏霏女士，届时公司高管将在线就公司2025年半年度业 绩、公司治理、发展战略、经营状况等投资者关心的问题，与投资者进行沟通与交流，欢迎 广大投资者踊跃参与。 特此公告。 天津力生制药股份有限公司 董事会 20 ...

Fund Establishments - Changjiang Gengzhi Fund has completed registration with a total scale of 3 billion yuan, focusing on new materials and high-end equipment sectors [2] - Xuzhou New Industry Special Mother Fund has been registered with a total scale of 3 billion yuan, targeting new energy and integrated circuits [2] - Lishui City has established a venture capital fund with a total scale of 2 billion yuan, supporting technology-driven startups [3] - Fujian Province has launched a 1 billion yuan publishing industry mother fund, focusing on cultural industry integration [3] - Ezhou Ge Dian Semiconductor Industry Fund has been registered with a total scale of 300 million yuan, focusing on the semiconductor industry [4] - Anhui Province plans to establish a 20 billion yuan artificial intelligence industry theme fund to support innovation projects [4] - Tianjin Heping District has registered its first QFLP fund with a capital of 54.5 million yuan, focusing on domestic alternatives and digital economy sectors [5] - Qinghai Guoding Electronic Information Venture Capital Fund has been established with a total scale of 150 million yuan, focusing on electronic information sectors [6] - Jiangxi Wanyan County has initiated a 500 million yuan mother fund, focusing on electronic information and non-metal materials [6] Investment Focus - The funds are primarily targeting emerging industries such as new energy, integrated circuits, and artificial intelligence [2][4] - The focus on technology-driven sectors is evident, with several funds aimed at supporting startups in high-tech fields [3][6] - The establishment of funds in various regions indicates a strategic push towards enhancing local industrial capabilities and innovation [2][4][5] Strategic Collaborations - Changjiang Chuangtou will leverage its management expertise to enhance investment in quality enterprises, fostering high-quality industrial development in Hubei [2] - The collaboration between various local governments and private sectors is aimed at optimizing industrial structures and promoting strategic partnerships [2][4][5] - The establishment of funds by companies like Tencent and KKR highlights the trend of leveraging private capital for regional development [8][9]

Group 1 - The company achieved a revenue of 732 million yuan and a net profit attributable to shareholders of 343 million yuan in H1 2025, representing a year-on-year increase of 235.04% [1] - The significant growth in net profit is primarily due to cash dividends received from Tian Shili Bio, in which the company's wholly-owned subsidiary, Central Pharmaceutical, holds a 12.15% stake, amounting to 303.75 million yuan [1] - The company maintains a gross margin of 59.16% and a net profit margin of 14.25% in H1 2025, reflecting improvements of 3 percentage points and 0.93 percentage points year-on-year, respectively [1] Group 2 - The company has identified over 300 quality projects and is preparing to establish an industrial merger and acquisition fund [2] - In H1 2025, the company invested 60.51 million yuan in R&D, with an investment rate exceeding 8%, resulting in multiple breakthroughs and the approval of three core products [2] - The company has enhanced its marketing and production capabilities, with significant sales growth in various products, including a 14% increase in sales revenue for urokinase injection and a 48% surge in external sales of heparin sodium injection [2]